Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genz-644470 vs Sevelamer Carbonate in Hyperphosphatemic CKD
NCT00853242Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2009
- Primary completion
- Aug 2009
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of genz-644470 in hyperphosphatemia (7 arms), sponsored by Sanofi. Primary endpoint: Change From Baseline in Serum Phosphorus at Day 22. Started Feb 2009; status: completed.
02
Drugs
genz-644470
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00853242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00853242.